Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

L.A. McKeown

September 09, 2025

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

Todd Neale

September 01, 2022

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

News Conference News ESC 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

Caitlin E. Cox

September 04, 2020

News Conference News ESC 2020

HESTIA, Simplified PESI Comparable for Triage to Outpatient PE Treatment: HOME-PE

Todd Neale

September 01, 2020

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

Medically Ill Pa+ent Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presentation ESC 2018

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presenter: Alex C. Spyropoulos

August 27, 2018

News Conference News ESC 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

Todd Neale

August 30, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

Advertisement

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

HESTIA, Simplified PESI Comparable for Triage to Outpatient PE Treatment: HOME-PE

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Novel Anticoagulants Showing Benefits in A-fib Subgroups

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content